Background
joel topf
SONAR: Is there a Signal in the Noise?

Atrosentan makes a return visit to NephJC, but now it goes beyond changes in proteinuria and shows improved kidney outcomes. Is it enough to overcome the fluid complications?

SONAR: Is there a Signal in the Noise?
Background
swapnil hiremath
Risk Stratifying A Heterogeneous Entity: IgA ...

This week, we will discuss a risk score which helps to prognosticate the most common glomerular disease. Not only is IgA most common - it is quite heterogeneous, which makes the problem of who should get treated quite difficult.

Risk Stratifying A Heterogeneous Entity: IgA Nephropathy
Background
joel topf
Fixing Hypernatremia: Acting Fast or Acting ...

They always said not to correct hypernatremia faster than 0.5 mmol/L/hour but what do they know and who are they anyways? New data questions this ancient dogma.

Fixing Hypernatremia: Acting Fast or Acting Slow?
Background
swapnil hiremath
The SGLT2i Crescendo with CREDENCE

This week, we will discuss the CREDENCE trial, simply the most important nephrology trial in a generation.

The SGLT2i Crescendo with CREDENCE
Background
swapnil hiremath
How can we ASCEND from the depths of ...

This week we look at the treatment of depression in hemodialysis patients. It is cognitive behavorial therapy versus sertraline.

How can we ASCEND from the depths of depression?

news